oral presentation on eras

• (888) 381-9509
• [email protected]
• Book a Meeting
• student login
• Student Login
• Our Services
• Our Story How it started
• Our Team Meet Our Advisors & Tutors
• Our Services How we can help you
• Our Difference Learn why we stand out
• Success Stories & Testimonials Hear the stories
• For Parents Learn why you should trust us
• In the News Read Our Stories
• Frequently Asked Questions Find answers
• MCAT Tutoring One-on-One Personalized Help
• MCAT Go An Audio Learning Experience
• MCAT Practice Exams Boost Your Score
• MCAT Prep App Videos, Flashcards & Q-Bank
• MCAT CARS Mastery Top-Rated CARS Video Course
• Pre-Med Coach Early High School Roadmap Planning
• College Admissions 11th & 12th Grade Pre-Med Consulting
• Direct Med Advising BS/MD Application Support
• Interview Preparation BS/MD Candidates
• Pre-Med Coach Pre-Application Development
• Application Advising Med School Admissions Support
• Personal Statement Editing Refine Your Narrative
• AMCAS Editing Application Editing
• Secondary Editing Secondary Application Editing
• Interview Preparation Realistic Practice
• CASPer Preparation Simulation & Coaching
• Ontario Application Support OMSAS Application
• Residency Advising Complete Match Support
• Residency Interview Preparation
• ERAS Personal Statement Refine Your Story
• USMLE STEP 1 Pass Your First Step
• Shelf Exams Ace your rotations
• USMLE STEP 2 Shine on your boards
• USMLE STEP 3 Conquer your final hurdle
• COMLEX LEVEL 1 and 2 Score higher
• Institutional Partners Enhance your student offering
• Organizational Partners Provide value to your students
• For High School Students Plan Your Future
• For MCAT Preparation Boost Your Score
• For Med School Admissions Secure Your Acceptance
• For Board Exam Prep Sharpen Critical Knowledge
• For Residency Matching Secure Preferred Placement
• Extracurricular Activities Apply now!
• Guidebooks Learn at Your Own Pace

How to Expertly Fill out the ERAS Experiences Section

Posted in: Residency

Table of Contents

The Experiences Section is a big part of your ERAS (electronic residency application service), and some residency applicants find the sections and instructions somewhat confusing. But this section of the application is crucial for matching with your preferred program .

In 2024, the MyERAS Application service made major updates to this section , including:

• A limit of only 10 experiences (previously no limit)
• Space to describe the 3 “most meaningful experiences” from the list
• Specific experience types (to help “programs easily identify and review specific experiences that align with their mission(s)”)
• New options for mission-focused characteristics of each experience to define the setting, focus area, and key characteristic (designed to “showcase the mission-focused characteristics of the experience”)
• Multiple short descriptions for each experience: roles, responsibilities, and context (previously, this was just one “Experiences Description” field)
• Optional “Impactful Experiences” question (for applicants to “describe any challenges or hardships that influenced their journey to residency”)

I’m Sahil Mehta, M.D., and I’ve helped hundreds of med school students successfully make it into their ideal residency. Below, I break down the parts of this section and tips that I give students when filling out the ERAS Experiences Section (which includes considerations for the most recent changes).

Skip to the tips.

What Are the Parts of the Experiences Section?

The Experiences Section allows you to list up to 10 experiences or activities that you engaged in as a med school student or pre-med student (or, in some cases, as an undergrad ) that demonstrate your strength as a candidate for medical residency.

This section breaks up each experience into multiple parts: 

• Type (category)
• Organization name
• Position title
• Start and end dates
• Primary focus area, if applicable
• Key characteristic developed or demonstrated, if applicable
• Description of the experience (1,020-character limit)

The description is arguably the most important piece because your writing must be interesting, professional, concise, and persuasive. You can find my suggestions for writing these descriptions later in this article.

Out of the 10 experiences, ERAS will ask you to choose your three most meaningful experiences. Under these three, you will write an additional description (up to 300 characters in length) explaining why these experiences impacted you most of all.

Read Next: A Guide to Supplemental ERAS Applications

Experience Types

Types are categories to better define what kind of experience you’re including. Residency programs understand that experiences can fall under more than type, but you must choose the one that best describes the experience or activity (you can’t select multiple categories).

You’ll be able to select from these experience types:

• Education/training (including clerkships, away rotations, subinternships, or structured observerships)
• Military service
• Professional organization (including at the local, regional, national, or international levels)
• Other extracurricular activity , club, hobby (including things like sports, music, theater, or student government)
• Teaching/ mentoring (including as a paid teacher, teaching assistant, or tutor)
• Volunteer/service/ advocacy (including unpaid experiences)
• Work (including paid clinical, nonclinical, business, or entrepreneurial experiences)

Primary Focus Areas

You can also list a primary focus for each experience. You may technically leave it blank, but I’d advise against that. Two or more focuses may apply to your experience, but you must choose only one. The types and primary focus areas overlap somewhat, but are used by program directors to organize information differently.

Here are the primary focus areas you can choose from:

• Basic science
• Clinical/translational science
• Community involvement/outreach
• Customer service
• Health care administration
• Improving access to health care
• Medical education
• Music/athletics/art
• Promoting wellness
• Public health
• Quality improvement
• Social justice/advocacy

Key Characteristics

I would recommend listing a key characteristic learned through each experience. You can leave it blank, but I would always try to choose one. Two or more may apply, but programs understand that you’re listing the characteristic that best describes what you learned.

Below are the key characteristics you’ll have to choose from:

• Communication
• Critical thinking and problem-solving
• Cultural humility and awareness
• Empathy and compassion
• Ethical responsibility
• Ingenuity and innovation
• Reliability and dependability
• Resilience and adaptability
• Self-Reflection and improvement
• Teamwork and leadership

It’s okay if your experience only occurred once, and it’s fine if you engage every week. Your residency application just wants to be clear on how often you have an “experience.”

Frequency types to choose from include:

• One time (not recurring)
• Daily (recurring) (more than two days a week)
• Weekly (recurring) (one or two days a week)
• Monthly (recurring)
• Quarterly (recurring)
• Annually (recurring)

Top Tips on Filling out the ERAS Experiences Section

I have helped hundreds of medical students with their residency applications. Don’t be stressed, MedSchoolCoach is here to help. Below, you can find my top tips for filling out the ERAS Experiences Section.

Get ERAS support from a Physician Advisor and join the 97% of MedSchoolCoach clients who match into US residency spots. 

1. write the descriptions like this.

The description is the most important part of the Experiences Section. Give yourself plenty of time to work on these. 

Try to answer the who, what, when, where, why, and how for each experience. The basic info included may answer the who, where, and when, but in the description you need to precisely describe:

• What — List your task(s) at this experience, your achievement(s) at this experience, what you learned.
• Why — Answer why did you engage in this experience, for what reason is it relevant to this application.
• How — Write how this experience demonstrated or developed characteristics that the program would find valuable, reflect how you grew.

All this must fit in only 1,020 characters. Not words, characters — that includes letters, spaces, and punctuation.

2. Write Your Most Meaningful Experiences Like This

Choose 3 of the 10 experiences to be your “most meaningful.” You get an additional 300 characters to explain why each of these is such an impactful experience.

Reflect on a “most meaningful experience” and explain why it was so impactful. Answer how it influenced you to be a stronger candidate for residency. Program directors are looking for descriptions that exemplify overcoming adversity, sophisticated introspection, and clear growth as a medical professional and as a human.

If you listed a key characteristic or primary focus area under a most meaningful experience, your 300-character description should explain why you chose that key characteristic or focus area.

WATCH: Standing Out on ERAS (Webinar)

3. Be Yourself

Programs don’t want just one type of applicant. They’re looking for a diverse range of candidates. Be true to yourself, and don’t make up or exaggerate experiences you think they want to hear.

What are you passionate about? Your passions should be evident through the Experiences Section. It’s okay if you talk about your dedication to the clarinet or to soccer or to a non-medical volunteer group, just make sure that it’s clear why this makes you a great candidate for a residency program.

4. Prioritize Relevant Work

Your number one priority is persuading the residency director that you are a good fit for that program. So, of course you should prioritize including your most relevant research, volunteering, extracurricular, and work experience in this section.

Often, any clinical experience you’ve done should be at the top of your Experiences Section. But this is where you can tailor your application toward your dream residency. If they’re highly involved in social justice, prioritize including your advocacy experiences. If they’re known for research, put your research experience at the top.

Read Next: Letter of Intent for Residency

5. Don’t Repeat Yourself

If you can help it, don’t repeat what you’ve already shown on other sections of the ERAS, such as the personal statement or letters of recommendation. Use the Experiences Section to complement the rest of your application.

There may be overlap, but focus on providing additional insight into your strength as a candidate wherever possible. In particular, your 300-character “most meaningful experiences” descriptions should not repeat information from the 1,020-character description, other activities, your MSPE Noteworthy Characteristics, or your well-crafted personal statement .

Learn More: Average Number of Residency Applications

6. Don’t Leave Blanks

Don’t leave optional fields blank if you can help it. According to an AAMC survey for the 2022/23 application cycle, about 55% of residency program directors said the “most meaningful experiences” helped them get a better picture of applicants. Around 35% used the key characteristics and primary focus areas to evaluate applications.

Also, try to fill out all 10 experiences. Although the quality of your experience descriptions is more important than the quantity or number of experiences, fewer than 10 experiences may indicate that you haven’t accomplished much or engaged with your community.

It might not make a huge difference if you have only 9 experiences, but just remember that the competition is fierce. Competitive residency applications utilize all the available space to their advantage.

7. Don’t Use Special Formatting

The ERAS application does not use rich formatting, so paragraph breaks, indentations, and bullet points may not translate correctly to the ERAS. Instead, write concise sentences in a single paragraph to avoid formatting errors. 

I recommend using a basic text editor (like TextEdit on a Mac or Notepad on a PC), rather than MS Word or Google Docs, for drafting your descriptions and most meaningful descriptions.

8. Start As Early As You Can

Don’t force yourself to rush. Taking your time is best for everyone, and starting early allows you to take your time. Give yourself 4-6 weeks to brainstorm which experiences to include, how best to describe them, and which ones to make your “most meaningful.”

Remember: Start early on all ERAS sections, especially your LORs (letters of recommendation),, since LOR authors may need plenty of time and reminders.

9. Proofread a Lot

Any errors will decrease your chances of acceptance. Typos and grammatical errors put your communication skills and dedication to excellence into question. Triple-check your work. Use a free trial of Grammarly or ProWritingAid. Ask your family, friends, peers, and professors to proofread your Experience Section.

Should You Answer the Impactful Experiences Question?

One of the 2024 updates is the addition of the “Impactful Experiences” question . Here’s what AAMC has to say about it:

“Applicants can describe any challenges or hardships that influenced their journey to residency. This could include experiences related to family background, financial background, community setting, educational experiences, and/or general life experiences. This question is intended for applicants who have overcome major challenges or obstacles.”

56% of applicants responded to this question in 2023. If you are comfortable sharing the relevant personal details and have overcome obstacles on your path to becoming a doctor, then you should answer this question. 

This is an optional question, used as part of the more holistic application review that the AAMC now encourages program directors to use during the residency application process. 

Tread carefully: This question is meant to help residency programs understand significant challenges and hardships that have impacted an applicant’s journey. If you try to answer this question with an experience that did not actually present a significant challenge to you, you may come across as inauthentic or immature to those reading your answers.

To know if and how you should answer this question, consider the following:

• Have you experienced substantial financial difficulty in the process of affording your education to this point (including undergrad and medical school)? If so, how did this impact you, and what did you do to overcome these difficulties?
• Did you grow up in a community setting that doesn’t traditionally lend itself to success? If so, what about your community setting was challenging? The AAMC mentions food scarcity, crime, poverty, and lack of access to medical care as a few examples that may apply here.
• Have you struggled with limited opportunities throughout your education to connect with mentors or access resources that would have helped you succeed more easily? Describe what resources you didn’t have and how you dealt with this to pursue a medical career.
• Has anything you’ve encountered as part of your family situation made a large impact on your journey to becoming a physician? Have you lost a family member, served as a caregiver while pursuing your degree(s), or experienced a significant experience such as divorce? Are you the first in your family to graduate college? Discuss how these have shaped your pursuit of medicine.

Increase Your Chances at Matching with Your Dream Program

I know, we’re all trying to get the good news on Match Day . It takes a long time and hard work, but it’s doable. There’s no shame in asking for help. You’ve made it this far, now let’s take that next step on your journey to residency, together.

And when you get that residency interview , we offer coaching for that, too.

Join the 97% of MedSchoolCoach clients who match into US residency. Pair up with an expert Physician Advisor to strengthen your CV, craft a stand-out ERAS application, ace your interviews, and land a spot in your choice specialty.

Sahil Mehta MD

Dr. Mehta is the founder of MedSchoolCoach and has guided thousands of successful medical school applicants. He is also a practicing physician in Boston where he specializes in vascular and interventional radiology.

See How We Can Help

Search for:, recent posts, medschoolcoach, dr. ken tao, recent blog posts.

How to Use COMSAEs to Excel on COMLEX: Study Tips & FAQs

Table of Contents Preparing for medical licensing exams can feel overwhelming, with the endless study hours and the constant pressure[...]

August 13, 2024

A Complete Guide to the Residency Match Process

Table of Contents The months leading up to medical school graduation are exciting, but also the beginning of the next[...]

July 1, 2024

Categorical vs Preliminary vs Advanced Residency Programs: A Primer for Residency Applicants

If you are applying to residency in the US through the NRMP match program, you may be confused about the[...]

September 30, 2021

The Pre-Med Journey: What it Takes to Get into Medical School

Thinking about applying to medical school? Discover what high school students need to know about obtaining a career in medicine.

Successfully Planning for the USMLE Step 1 and 2 CK

Get ready for the USMLE Step 1 and Step 2 with this free guide to study planning and resource utilization.

100 MCAT Study Tips

Taking the MCAT? These 100 tips and tricks will help you ace the MCAT.

Call us at (888) 381-9509

Call Us Now

Or, Schedule a Meeting Below

• Today's news
• Reviews and deals
• Climate change
• 2024 election
• Fall allergies
• Health news
• Mental health
• Sexual health
• Family health
• So mini ways
• Unapologetically
• Buying guides

Entertainment

• How to Watch
• My Portfolio
• Latest News
• Stock Market
• Biden Economy
• Stocks: Most Actives
• Stocks: Gainers
• Stocks: Losers
• Trending Tickers
• World Indices
• US Treasury Bonds Rates
• Top Mutual Funds
• Options: Highest Open Interest
• Options: Highest Implied Volatility
• Basic Materials
• Communication Services
• Consumer Cyclical
• Consumer Defensive
• Financial Services
• Industrials
• Real Estate
• Stock Comparison
• Advanced Chart
• Currency Converter
• Credit Cards
• Balance Transfer Cards
• Cash-back Cards
• Rewards Cards
• Travel Cards
• Credit Card Offers
• Best Free Checking
• Student Loans
• Personal Loans
• Car insurance
• Mortgage Refinancing
• Mortgage Calculator
• Morning Brief
• Market Domination
• Market Domination Overtime
• Asking for a Trend
• Opening Bid
• Stocks in Translation
• Lead This Way
• Good Buy or Goodbye?
• Financial Freestyle
• Capitol Gains
• Living Not So Fabulously
• Fantasy football
• Pro Pick 'Em
• College Pick 'Em
• Fantasy baseball
• Fantasy hockey
• Fantasy basketball
• Download the app
• Daily fantasy
• Scores and schedules
• GameChannel
• World Baseball Classic
• Premier League
• CONCACAF League
• Champions League
• Motorsports
• Horse racing
• Newsletters

New on Yahoo

• Privacy Dashboard

Yahoo Finance

Tonix pharmaceuticals announces oral presentation and three poster presentations at the 2024 military health system research symposium (mhsrs).

Oral presentation highlights TNX-102 SL (sublingual cyclobenzaprine HCl) treatment in Phase 3 RESILIENT study demonstrating statistically significant improvement in fibromyalgia nociplastic pain and in all six key secondary endpoints, including sleep quality

Posters highlighting other TNX-102 SL programs in clinical development, including acute stress disorder

Poster demonstrating automated high-throughput assay enabling screening for therapeutics to accelerate wound healing

CHATHAM, N.J., Aug. 21, 2024 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a fully-integrated biopharmaceutical company with marketed products and a pipeline of development candidates, today announced that representatives of the Company will deliver an oral presentation and present three posters at the 2024 Military Health System Research Symposium (MHSRS), being held August 26-29, 2024, in Kissimmee, Fla. Details on the presentations can be found below.

Copies of the Company’s oral presentation and posters will be available under the Scientific Presentations tab of the Tonix website at www.tonixpharma.com following the conference. Additional meeting information can be found on the MHSRS website here .

Oral Presentation

Poster Presentations

Tonix Pharmaceuticals Holding Corp. *

Tonix is a fully-integrated biopharmaceutical company focused on developing, licensing and commercializing therapeutics to treat and prevent human disease and alleviate suffering. Tonix recently announced the U.S. Department of Defense (DoD), Defense Threat Reduction Agency (DTRA) awarded it a contract for up to $34 million over five years in an Other Transaction Agreement (OTA) to develop TNX-4200 small molecule broad-spectrum antiviral agents targeting CD45 for the prevention or treatment of infections to improve the medical readiness of military personnel in biological threat environments. Tonix owns and operates a state-of-the art infectious disease research facility in Frederick, MD. The company’s Good Manufacturing Practice (GMP)-capable advanced manufacturing facility in Dartmouth, MA was purpose-built to manufacture TNX-801 and the GMP suites are ready to be reactivated in case of a national or international emergency. Tonix’s development portfolio is focused on central nervous system (CNS) disorders. Tonix’s priority is to submit a New Drug Application (NDA) to the FDA in the second half of 2024 for TNX-102 SL, a product candidate for which two statistically significant Phase 3 studies have been completed for the management of fibromyalgia. The FDA has granted Fast Track designation to TNX-102 SL for the management of fibromyalgia. TNX-102 SL is also being developed to treat acute stress reaction. Tonix’s CNS portfolio includes TNX-1300 (cocaine esterase), a biologic designed to treat cocaine intoxication that has Breakthrough Therapy designation. Tonix’s immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix also has product candidates in development in the areas of rare disease and infectious disease. Tonix Medicines, our commercial subsidiary, markets Zembrace® SymTouch® (sumatriptan injection) 3 mg and Tosymra® (sumatriptan nasal spray) 10 mg for the treatment of acute migraine with or without aura in adults.

*Tonix’s product development candidates are investigational new drugs or biologics and have not been approved for any indication.

Zembrace SymTouch and Tosymra are registered trademarks of Tonix Medicines. All other marks are property of their respective owners.

This press release and further information about Tonix can be found at www.tonixpharma.com .

Forward Looking Statements

Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as “anticipate,” “believe,” “forecast,” “estimate,” “expect,” and “intend,” among others. These forward-looking statements are based on Tonix's current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, risks related to the failure to obtain FDA clearances or approvals and noncompliance with FDA regulations; risks related to the failure to successfully market any of our products; risks related to the timing and progress of clinical development of our product candidates; our need for additional financing; uncertainties of patent protection and litigation; uncertainties of government or third party payor reimbursement; limited research and development efforts and dependence upon third parties; and substantial competition. As with any pharmaceutical under development, there are significant risks in the development, regulatory approval and commercialization of new products. Tonix does not undertake an obligation to update or revise any forward-looking statement. Investors should read the risk factors set forth in the Annual Report on Form 10-K for the year ended December 31, 2023, as filed with the Securities and Exchange Commission (the “SEC”) on April 1, 2024, and periodic reports filed with the SEC on or after the date thereof. All of Tonix's forward-looking statements are expressly qualified by all such risk factors and other cautionary statements. The information set forth herein speaks only as of the date thereof.

Investor Contact

Jessica Morris Tonix Pharmaceuticals [email protected] (862) 904-8182

Peter Vozzo ICR Westwicke [email protected] (443) 213-0505

Media Contact

Ray Jordan Putnam Insights [email protected] (949) 245-5432

UVA Doctoral Students Showcase Potential of Advanced Data Science Research

Doctoral students from the University of Virginia’s School of Data Science kicked off the new academic year with a research showcase, highlighting the broad range of areas that advanced studies in data science can help illuminate. 

The event also served as a celebration of the doctoral program and what it means to the mission of the School of Data Science. 

"The Ph.D. program is kind of the perfect mixing of our research endeavors and our educational endeavors," said Thomas Stewart , an associate professor of data science and Ph.D. program director, in opening remarks.

Don Brown , senior associate dean for research and the Quantitative Foundation Distinguished Professor in Data Science, noted that the event was "arguably the best part of the summer," as faculty, staff, and students are given the opportunity to see first-hand the high-level research that Ph.D. students at the School of Data Science had been pursuing in recent months.

Brown also urged audience members as they listened to the oral presentations from second-year students and viewed the research posters from third-year students to ask challenging questions, saying that was "the biggest gift you can give the person" who was presenting.

Oral presentations were delivered by 13 second-year Ph.D. students, whose research covered everything from health care chatbots to deep dives into a wide range of methodological techniques, as well as issues pertaining to large language models. 

Later, 13 third-year students presented research posters that addressed critical issues such as health care, K-12 education, the environment, and many others. 

Following the presentations, an awards ceremony was held, one that both recognized the research that had just been discussed and that celebrated the achievements of the School of Data Science doctoral program — its students, faculty, and staff — over the previous year. Stewart also highlighted a sampling of recent research publications from the School's doctoral students. 

As the day wound down, Jeffrey Blume , Quantitative Foundation Associate Dean for Academic and Faculty Affairs in Data Science, urged the newest group of School of Data Science Ph.D. students in attendance to take inspiration from what they had just seen.

"For those students who are new and who are here, you get a sense of what people are doing their first couple of years, so it's something to look forward to. We look forward to seeing your names up here on publications and listening to your work," he said. 

The 2024-25 academic year will mark the third full year of UVA’s data science doctoral program , which launched in fall 2022. And, for the first time, students in all academic programs will be able to take classes and collaborate with faculty and classmates at the new home of the School of Data Science, which held its grand opening in April .  

Awards 

Best Oral Presentations

• Ethan Nelson , who discussed his work that examined whether signal neural networks can evolve to capture how signals travel between neurons over time
• Ahson Saiyed , who presented his enhanced benchmark, called TAXI 2.0, for evaluating the capacity of knowledge editing methods to leverage batched property edits to make consistent categorical knowledge edits in large language models

Best Research Poster

• Karolina Naranjo-Velasco , who presented her work on facilitating data-drive approaches to legal text analysis of documents from the Colombian Constitutional Court
• Jason Wang , who presented his work assessing computer vision-based worker poster analysis methods

Leadership and Service Award

• Beau LeBlond , a third-year Ph.D. student 

Outstanding Teaching Award

• Jonathan Kropko , a Quantitative Foundation Associate Professor of Data Science

Outstanding Mentoring Award

• Stephen Baek , a Quantitative Foundation Associate Professor of Data Science

Outstanding Student Support Award

• Kylen Baskerville , program manager for the School of Data Science

Full list of second-year oral presentations

• Supervising faculty: Stephen Baek
• Supervising faculty: Don Brown
• Supervising faculty: Heman Shakeri
• Supervising faculty: Jeffrey Blume
• Supervising faculty: John Darrell Van Horn
• Supervising faculty: Sheng Li
• Supervising faculty: Teague Henry
• Supervising faculty: Tom Hartvigsen
• Supervising faculty: Sheng Li and Tom Hartvigsen
• Supervising faculty: Alex Gates

Full list of third-year poster presentations

• Zhanwen Chen : Video Understanding through Video-to-Text Representation Learning
• Supervising faculty: Thomas Stewart
• Supervising faculty: Jonathan Kropko
• Supervising faculty: William Basener
• Supervising faculty: Jess Reia and Jeffrey Blume
• Supervising faculty: William Basener  

Effective Communication Strategies for Ph.D. Research Presentations

UVA’s School of Data Science Honors the Class of 2024

School of Data Science Ph.D. Students and Faculty Member Named To Raven Society

Ph.D., Data Science: Jiahao Tian Successfully Defends Dissertation

Get the latest news.

Subscribe to receive updates from the School of Data Science.

• Prospective Student
• School of Data Science Alumnus
• UVA Affiliate
• Industry Member

ADOCIA to Deliver Oral Presentations on AdoShell® and AdoGel® at EASD Annual Meeting

29 Aug 2024 18:00 CEST

Regulatory News:

Adocia (Euronext Paris: FR0011184241 – ADOC, the “Company”), a clinical-stage biopharmaceutical company focused on the research and development of innovative therapeutic solutions for the treatment of diabetes and obesity, today announced oral presentations at EASD 2024, unveiling the latest results obtained on AdoShell ® Islets, an immunoprotective hydrogel containing islets of Langerhans for the treatment of diabetes by cell therapy, and on AdoGel ® Sema, a technology enabling the sustained release of semaglutide.

The 60 th annual congress of the EASD (European Association for the Study of Diabetes) will be held from September 9 to 13, in Madrid, Spain.

AdoShell ® Islets

• Title : ADO12, a non-fibrotic immunoprotective hydrogel containing human islets shows efficient and sustained in vivo functionality for clinical use
• Day and Time : Friday, September 13, 2024 - 11:00 -11:15 a.m.
• Session : Protection in Islet Transplantation (OP-37; 219)
• Room : Madrid Hall
• Authors : Anne-Lise Gaffuri, Xavier Gaume, Romain Besnard, Julie Brun, Camille Gautier, Ouardane Jouannot, Nicolas Laurent, Rosy Eloy, Karim Bouzakri, François Pattou, Olivier Soula
• Links : More details, including the abstract, are available on the EASD website .

About AdoShell ® Islets:

AdoShell ® Islets is a new immunoprotective hydrogel encapsulating islets of Langerhans. This permeable hydrogel allows the diffusion of insulin and glucose while preventing the invasion of antibodies and immune cells. This implantable device, which is fully retrievable by laparoscopy, has the potential to enable islet transplantation without the need for immunosuppression, offering an unprecedented solution for curing people with diabetes.

AdoShell ® Islets have shown sustained survival and functionality of human islets in vitro for over 4 months. This long-term survival has been confirmed in vivo in immunodeficient mice, with a stable insulin or C-peptide secretion over 3 months, absence of fibrotic encapsulation and survival of functional islets.

Adocia is currently working with regulatory authorities to validate a first clinical trial, which could take place as early as 2025.

AdoGel ® Sema

• Title: Development of a once-a-month formulation of semaglutide from an innovative injectable and biodegradable hydrogel
• Day and time: Tuesday, September 10, 2024 - 14:00 -14:15
• Session: Hot of the press novel incretins (B. SO 062 - oral 746)
• Room: station 11
• Authors: Romain Besnard, Audrey Marechal, Claire Mégret, Sana Hakim, Jenny Erales, Ulysse Naessens, Maud Fumex, Martin Gaudier, Olivier Soula, You-Ping Chan, Emmanuel Dauty
• Links: More details, including the abstract, are available on the EASD website .

About AdoGel ® :

Designed to enable the long-acting delivery of peptides, AdoGel ® is currently being studied for semaglutide (GLP‑1). The unique AdoGel ® technology aims to offer monthly or even quarterly peptide injections, replacing the weekly injections currently on the market.

The results showed that a regular release of semaglutide over one month associated with limited early release is achievable. This could be a real benefit for treatment efficacy and safety as well as patient compliance by limiting the injection frequencies and reducing side effects

EASD 2024 is the 60 th annual congress of the European Association for the Study of Diabetes (EASD), a non-profit medical scientific association that supports and promotes the application of diabetes research. The association was founded in 1965 and is one of the world's largest networks of diabetologists.

The congress brings together key opinion leaders, corporate executives, scientists, physicians, researchers, caregivers and students interested in diabetes and related topics. The aim of the EASD Annual Congress is to encourage excellence in diabetes management through research and education.

About Adocia

Adocia is a biotechnology company specializing in the discovery and development of therapeutic solutions in the field of metabolic diseases, primarily diabetes and obesity.

The Company has a broad portfolio of drug candidates based on four proprietary technology platforms: 1) The BioChaperone ® technology for the development of new generation insulins and products combining different hormones; 2) AdOral ® , an oral peptide delivery technology; 3) AdoShell ® , an immunoprotective biomaterial for cell transplantation, with an initial application in pancreatic cells transplantation; and 4) AdoGel ® , a long-acting drug delivery platform.

Adocia holds more than 25 patent families. Based in Lyon, the company has about 80 employees. Adocia is listed on the regulated market of Euronext ™ Paris (Euronext: ADOC; ISIN: FR0011184241).

This press release contains certain forward-looking statements concerning Adocia and its business. Such forward-looking statements are based on assumptions that Adocia considers as being reasonable. However, there can be no guarantee that the estimates contained in such forward-looking statements will be achieved, as such estimates are subject to numerous risks including those set forth in the “Risk Factors” section of the universal registration document that was filed with the French Autorité des marchés financiers on April 29, 2024, available at www.adocia.com . Those risks include uncertainties inherent in Adocia's short- or medium-term working capital requirements, in research and development, future clinical data, analyses and the evolution of economic conditions, the financial markets and the markets in which Adocia operates, which could impact the Company's short-term financing requirements and its ability to raise additional funds. The forward-looking statements contained in this press release are also subject to risks not yet known to Adocia or not considered as material by Adocia at this time. The occurrence of all or part of such risks could cause the actual results, financial conditions, performances, or achievements of Adocia be materially different from those mentioned in the forward-looking statements.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240829633824/en/

Olivier Soula CEO [email protected] +33 (0)4 72 610 610 www.adocia.com

Ulysse Communication

Adocia Press & Investor Relations Bruno Arabian Nicolas Entz [email protected] + 33 (0)6 87 88 47 26

BusinessWire

Company Name

FR0011184241

Company press releases subscription

• AEX index Stocks
• AEX ESG Stocks
• Structured products
• Index options
• Index futures
• Stock options
• Dividend derivatives
• Stock futures
• Quote Vendor Codes
• Euronext regulated
• Euronext Growth
• Euronext Access
• Expert Market
• BEL 20 Stocks
• Structured Products
• ISEQ 20 Stocks
• Irish Government Bonds
• Euronext Milan
• Euronext Growth Milan
• Euronext Star Milan
• Euronext Global Equity Market
• Trading After Hours
• MIB ESG Stocks
• Euronext Access Milan
• All derivatives
• Euronext Expand
• Top performers
• OBX ESG Stocks
• OSEBX stocks
• OSEFX Stocks
• Seafood Stocks
• Shipping Stocks
• Equity indices
• Nordic Alternative Bond Market
• Bond indices
• Derivative products
• Financial calendars
• Primary insiders
• CAC 40 Stocks
• CAC 40 ESG Stocks
• All Markets
• Listing sponsors
• Euronext Tech Leaders
• Family business
• ESG indices
• Indices documents
• Indices news
• Index consultations
• Contact Euronext indices
• Oslo Mutual Funds
• Directory / search
• Bid-Only trading status
• Trading Turbos in the Netherlands
• Index Futures
• Index Options
• Stock Options
• Stock Futures
• Dividend Derivatives
• ETF Options
• Contracts specifications
• Wholesale Trading
• Quote vendor codes
• Quotes snapshot
• Milling Wheat futures
• Rapeseed futures
• Corn futures
• European Durum Wheat Futures
• Milling Wheat options
• Rapeseed options
• Corn options
• Trading calendars
• Commitments of Traders (CoT) report
• Bid & Ask
• Contract Specifications
• Position Management
• Intrinsic Value
• Premium & Valuation
• Euronext News
• Quality of execution
• Trading hours & Holidays
• Contract specifications
• Class level
• Product group level
• Cash Notices / Corporate actions
• All Corporate Actions
• Unusual Contract Sizes, Dividends
• Corporate Action Services
• Corporate Action Policies
• Derivatives notices
• Suspended instruments
• Stressed Market Conditions
• Breach of Double Cap limits
• Exceptional Market Conditions
• Miscellaneous short messages
• Market status
• Members list
• Issuers compliance
• Where to find

• Communities Pre-Med Medical Resident Audiology Dental Optometry Pharmacy Physical Therapy Podiatry Psychology Rehab Sci Veterinary
• What's new Trending New posts Latest activity
• Support Account Help Confidential Advising
• Vision, Values and Policies
• Medical Student Communities
• Medical Students (MD)

ERAS question on research

• Thread starter premed2000
• Start date Aug 30, 2018

Full Member

• Aug 30, 2018

MedSchoolGurus

Usmle tutor.

• Sep 2, 2018

Typically, posters are accompanied by an accepted abstract. I would list the accepted abstract you were an author on, but not the poster itself. Does that make sense?  

• Sep 3, 2018

MedSchoolGurus said: Typically, posters are accompanied by an accepted abstract. I would list the accepted abstract you were an author on, but not the poster itself. Does that make sense? Click to expand...

If you did not present the poster, I would not list the poster at all. The abstract itself was likely peer reviewed and not all abstracts that were submitted were accepted for publication.  

• Sep 4, 2018

I would argue the contrary, if you contributed significantly to the work of the poster such that you are a listed author this should deserve a spot on your CV and thus your ERAS. For example consider the hypothetical case where a student is unable to attend and has to have a colleague present a poster that is entirely their work (not applicable here that I know of, just an example). It would be foolish to say they must then strike that entire line off of their CV/ERAS simply due to a scheduling issue. Assuming OP is not first author on these posters, I think it's fair to say nearly anyone seeing the item listed will recognize OP likely did not present it, but still contributed to its creation and the project at large. Thus, it's not like there is deception going on here. I say it's perfectly fine to list these. (full disclosure, I'm an M3 and this is only my opinion and is entirely based on conversations i've had and discussions I've read)  

Eh. I know a fellow who worked with a med student, then intern, on her fellow scholarly project, and got accepted to PAS (big Peds conference), but couldn’t go, so had the med student/intern present it. I imagine she still listed the poster on her CV. OP—if someone reviews the abstracts submitted and your abstract is accepted to a conference, then it is peer reviewed. Just put “[Abstract]” after the title and list either the conference, or the subsequent journal that the abstracts were published in (PAS publishes all abstracts in Pediatrics in like January following the May conference).  

• Sep 5, 2018

is it ok to list an abstract that you were a part of but didnt present if that project becomes a publication that you obviously also list? is that double dipping?  

Are you guys listing your publications by the author last name in ascending alphabetical order (like what it says on the ERAS 2019 guide), or listing like how it is seen on your paper/abstract/poster? It just seems so weird to list all my publications in alphabetic order... how will they know I’m first author??  

So I'm listing all my accepted conference abstracts/posters as just the poster, even if I was not the presenter. I heard programs don't like it when you double dip the abstract. However I'm a bit confused about the format for listing authors....according to ERAS is it supposed to be Smith, J., Bush, G., Trump, D. ? That just looks funny to me  

• Sep 6, 2018

bonemann said: is it ok to list an abstract that you were a part of but didnt present if that project becomes a publication that you obviously also list? is that double dipping? Click to expand...

sniderwes said: However I'm a bit confused about the format for listing authors....according to ERAS is it supposed to be Smith, J., Bush, G., Trump, D. ? That just looks funny to me Click to expand...

mvenus929 said: If you didn't present, I would just list the publication. If you didn't present, and there isn't yet a publication, you can list the abstract. If you presented the poster, you can list both the poster presentation and the publication (though some people frown on that--I think if you did the work to present, you should get credit for that too). There's varying opinions of what to do if you both presented the poster and don't yet have a publication--whether you should list both the poster presentation and the abstract. What's the confusion? That's how it's done in a lot of journals (except there are semi-colons instead of commas between individuals' names ). You can list the first initial without the period if you'd like. Click to expand...

sniderwes said: My confusion was that I usually see research listed Smith J, Bush G, Trump D with no periods in between each author like the way ERAS seems to suggest we do it. Click to expand...

moyamoya6 said: Are you going to list the authors in alphabetical order? Or nah? Click to expand...

sniderwes said: Why would you do that? Just list it by first author, second author, etc. Click to expand...

moyamoya6 said: Because the ERAS guide said something about listing it in ascending alphabetical order, so wasn’t sure if I should follow their directions or not. Click to expand...

Similar threads

• surelymedical
• Sep 25, 2023

• JuicedToTheSocks
• Aug 22, 2023

• stellarartois
• Aug 7, 2024

• hollisterdoc
• Jan 24, 2024

• Dr.SPAC3MAN
• This site uses cookies to help personalize content, tailor your experience and to keep you logged in if you register. By continuing to use this site, you are consenting to our use of cookies and terms of service . Accept Learn more…

Get the Reddit app

/r/medicalschool is an international community for medical students

Is it weird to list on ERAS that you gave two presentations at the same conference?

Our school had an "online" research conference where we could submit case presentations. I submitted two, and our director said that we could count our submissions as oral presentations on ERAS.

Would it be weird to list two oral presentations for the same conference on ERAS? I don't really have much research so these will stand out.

By continuing, you agree to our User Agreement and acknowledge that you understand the Privacy Policy .

Enter the 6-digit code from your authenticator app

You’ve set up two-factor authentication for this account.

Enter a 6-digit backup code

Create your username and password.

Reddit is anonymous, so your username is what you’ll go by here. Choose wisely—because once you get a name, you can’t change it.

Reset your password

Enter your email address or username and we’ll send you a link to reset your password

Check your inbox

An email with a link to reset your password was sent to the email address associated with your account

Choose a Reddit account to continue